首页 > 最新文献

PLoS Medicine最新文献

英文 中文
Evaluation of an online intervention for improving stroke survivors’ health-related quality of life: A randomised controlled trial 在线干预对改善中风幸存者健康相关生活质量的评价:一项随机对照试验
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-04-01 DOI: 10.1371/journal.pmed.1003966
Ashleigh Guillaumier, N. Spratt, M. Pollack, A. Baker, P. Magin, A. Turner, C. Oldmeadow, Clare E Collins, R. Callister, Christopher Levi, A. Searles, S. Deeming, Brigid Clancy, B. Bonevski
Background The aim of this trial was to evaluate the effectiveness of an online health behaviour change intervention—Prevent 2nd Stroke (P2S)—at improving health-related quality of life (HRQoL) amongst stroke survivors at 6 months of follow-up. Methods and findings A prospective, blinded-endpoint randomised controlled trial, with stroke survivors as the unit of randomisation, was conducted between March 2018 and November 2019. Adult stroke survivors between 6 and 36 months post-stroke with capacity to use the intervention (determined by a score of ≥4 on the Modified Rankin Scale) and who had access and willingness to use the internet were recruited via mail-out invitations from 1 national and 1 regional stroke registry. Participants completed baseline (n = 399) and 6-month follow-up (n = 356; 89%) outcome assessments via computer-assisted telephone interviewing (CATI). At baseline the sample had an average age of 66 years (SD 12), and 65% were male. Randomisation occurred at the end of the baseline survey; CATI assessors and independent statisticians were blind to group allocation. The intervention group received remote access for a 12-week period to the online-only P2S program (n = 199; n = 28 lost at follow-up). The control group were emailed and posted a list of internet addresses of generic health websites (n = 200; n = 15 lost at follow-up). The primary outcome was HRQoL as measured by the EuroQol Visual Analogue Scale (EQ-VAS; self-rated global health); the outcome was assessed for differences between treatment groups at follow-up, adjusting for baseline measures. Secondary outcomes were HRQoL as measured by the EQ-5D (descriptive health state), diet quality, physical activity, alcohol consumption, smoking status, mood, physical functioning, and independent living. All outcomes included the variable ‘stroke event (stroke/transient ischaemic attack/other)’ as a covariate, and analysis was intention-to-treat. At 6 months, median EQ-VAS HRQoL score was significantly higher in the intervention group than the control group (85 vs 80, difference 5, 95% CI 0.79–9.21, p = 0.020). The results were robust to the assumption the data were missing at random; however, the results were not robust to the assumption that the difference in HRQoL between those with complete versus missing data was at least 3 points. Significantly higher proportions of people in the intervention group reported no problems with personal care (OR 2.17, 95% CI 1.05–4.48, p = 0.0359) and usual activities (OR 1.66, 95% CI 1.06–2.60, p = 0.0256) than in the control group. There were no significant differences between groups on all other secondary outcomes. The main limitation of the study is that the sample comprises mostly ‘well’ stroke survivors with limited to no disability. Conclusions The P2S online healthy lifestyle program improved stroke survivors’ self-reported global ratings of HRQoL (as measured by EQ-VAS) at 6-month follow-up. Online platforms represent a promising tool
本试验的目的是评估在线健康行为改变干预-预防第二次卒中(P2S) -在改善中风幸存者6个月随访时与健康相关的生活质量(HRQoL)方面的有效性。方法和发现2018年3月至2019年11月进行了一项前瞻性、盲终点随机对照试验,以中风幸存者为随机化单位。中风后6至36个月有能力使用干预措施的成年中风幸存者(由修正兰金量表得分≥4分确定),并有机会和意愿使用互联网,通过邮寄邀请从1个国家和1个地区中风登记处招募。参与者完成了基线(n = 399)和6个月的随访(n = 356;89%)通过计算机辅助电话访谈(CATI)进行结果评估。在基线时,样本的平均年龄为66岁(标准差12),65%为男性。随机化发生在基线调查结束时;CATI评估人员和独立统计人员对分组分配不知情。干预组接受为期12周的远程访问在线P2S计划(n = 199;随访时N = 28)。对照组通过电子邮件发送并张贴一份通用健康网站的地址列表(n = 200;随访时丢失15例)。主要终点是HRQoL,由EuroQol视觉模拟量表(EQ-VAS;自评全球健康);在随访中评估治疗组之间的差异,并根据基线测量进行调整。次要结局为HRQoL,以EQ-5D(描述性健康状态)、饮食质量、身体活动、饮酒、吸烟状况、情绪、身体功能和独立生活来衡量。所有结果包括变量“卒中事件(卒中/短暂性缺血性发作/其他)”作为协变量,分析是意向治疗。6个月时,干预组EQ-VAS HRQoL中位数评分显著高于对照组(85 vs 80,差异5,95% CI 0.79 ~ 9.21, p = 0.020)。对于数据随机丢失的假设,结果是稳健的;然而,结果并不足以证明数据完整者与缺失者的HRQoL差异至少为3分。干预组患者在个人护理(OR 2.17, 95% CI 1.05-4.48, p = 0.0359)和日常活动(OR 1.66, 95% CI 1.06-2.60, p = 0.0256)方面没有出现问题的比例明显高于对照组。各组间其他次要结果无显著差异。该研究的主要局限性在于,样本大多是“健康”的中风幸存者,只有有限的残疾或没有残疾。结论P2S在线健康生活方式项目改善了脑卒中幸存者在6个月随访时自我报告的HRQoL总体评分(以EQ-VAS测量)。在线平台是吸引和支持一些中风幸存者的一个很有前途的工具。澳大利亚新西兰临床试验注册中心ACTRN12617001205325。
{"title":"Evaluation of an online intervention for improving stroke survivors’ health-related quality of life: A randomised controlled trial","authors":"Ashleigh Guillaumier, N. Spratt, M. Pollack, A. Baker, P. Magin, A. Turner, C. Oldmeadow, Clare E Collins, R. Callister, Christopher Levi, A. Searles, S. Deeming, Brigid Clancy, B. Bonevski","doi":"10.1371/journal.pmed.1003966","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003966","url":null,"abstract":"Background The aim of this trial was to evaluate the effectiveness of an online health behaviour change intervention—Prevent 2nd Stroke (P2S)—at improving health-related quality of life (HRQoL) amongst stroke survivors at 6 months of follow-up. Methods and findings A prospective, blinded-endpoint randomised controlled trial, with stroke survivors as the unit of randomisation, was conducted between March 2018 and November 2019. Adult stroke survivors between 6 and 36 months post-stroke with capacity to use the intervention (determined by a score of ≥4 on the Modified Rankin Scale) and who had access and willingness to use the internet were recruited via mail-out invitations from 1 national and 1 regional stroke registry. Participants completed baseline (n = 399) and 6-month follow-up (n = 356; 89%) outcome assessments via computer-assisted telephone interviewing (CATI). At baseline the sample had an average age of 66 years (SD 12), and 65% were male. Randomisation occurred at the end of the baseline survey; CATI assessors and independent statisticians were blind to group allocation. The intervention group received remote access for a 12-week period to the online-only P2S program (n = 199; n = 28 lost at follow-up). The control group were emailed and posted a list of internet addresses of generic health websites (n = 200; n = 15 lost at follow-up). The primary outcome was HRQoL as measured by the EuroQol Visual Analogue Scale (EQ-VAS; self-rated global health); the outcome was assessed for differences between treatment groups at follow-up, adjusting for baseline measures. Secondary outcomes were HRQoL as measured by the EQ-5D (descriptive health state), diet quality, physical activity, alcohol consumption, smoking status, mood, physical functioning, and independent living. All outcomes included the variable ‘stroke event (stroke/transient ischaemic attack/other)’ as a covariate, and analysis was intention-to-treat. At 6 months, median EQ-VAS HRQoL score was significantly higher in the intervention group than the control group (85 vs 80, difference 5, 95% CI 0.79–9.21, p = 0.020). The results were robust to the assumption the data were missing at random; however, the results were not robust to the assumption that the difference in HRQoL between those with complete versus missing data was at least 3 points. Significantly higher proportions of people in the intervention group reported no problems with personal care (OR 2.17, 95% CI 1.05–4.48, p = 0.0359) and usual activities (OR 1.66, 95% CI 1.06–2.60, p = 0.0256) than in the control group. There were no significant differences between groups on all other secondary outcomes. The main limitation of the study is that the sample comprises mostly ‘well’ stroke survivors with limited to no disability. Conclusions The P2S online healthy lifestyle program improved stroke survivors’ self-reported global ratings of HRQoL (as measured by EQ-VAS) at 6-month follow-up. Online platforms represent a promising tool ","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48940128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis 慢性肾脏疾病的症状负担与健康相关的生活质量:一项全球系统综述和荟萃分析
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-04-01 DOI: 10.1371/journal.pmed.1003954
B. Fletcher, Sarah Damery, O. Aiyegbusi, N. Anderson, M. Calvert, P. Cockwell, James Ferguson, M. Horton, Muirne C. S. Paap, C. Sidey-Gibbons, A. Slade, Neil Turner, D. Kyte
Background The importance of patient-reported outcome measurement in chronic kidney disease (CKD) populations has been established. However, there remains a lack of research that has synthesised data around CKD-specific symptom and health-related quality of life (HRQOL) burden globally, to inform focused measurement of the most relevant patient-important information in a way that minimises patient burden. The aim of this review was to synthesise symptom prevalence/severity and HRQOL data across the following CKD clinical groups globally: (1) stage 1–5 and not on renal replacement therapy (RRT), (2) receiving dialysis, or (3) in receipt of a kidney transplant. Methods and findings MEDLINE, PsycINFO, and CINAHL were searched for English-language cross-sectional/longitudinal studies reporting prevalence and/or severity of symptoms and/or HRQOL in CKD, published between January 2000 and September 2021, including adult patients with CKD, and measuring symptom prevalence/severity and/or HRQOL using a patient-reported outcome measure (PROM). Random effects meta-analyses were used to pool data, stratified by CKD group: not on RRT, receiving dialysis, or in receipt of a kidney transplant. Methodological quality of included studies was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data, and an exploration of publication bias performed. The search identified 1,529 studies, of which 449, with 199,147 participants from 62 countries, were included in the analysis. Studies used 67 different symptom and HRQOL outcome measures, which provided data on 68 reported symptoms. Random effects meta-analyses highlighted the considerable symptom and HRQOL burden associated with CKD, with fatigue particularly prevalent, both in patients not on RRT (14 studies, 4,139 participants: 70%, 95% CI 60%–79%) and those receiving dialysis (21 studies, 2,943 participants: 70%, 95% CI 64%–76%). A number of symptoms were significantly (p < 0.05 after adjustment for multiple testing) less prevalent and/or less severe within the post-transplantation population, which may suggest attribution to CKD (fatigue, depression, itching, poor mobility, poor sleep, and dry mouth). Quality of life was commonly lower in patients on dialysis (36-Item Short Form Health Survey [SF-36] Mental Component Summary [MCS] 45.7 [95% CI 45.5–45.8]; SF-36 Physical Component Summary [PCS] 35.5 [95% CI 35.3–35.6]; 91 studies, 32,105 participants for MCS and PCS) than in other CKD populations (patients not on RRT: SF-36 MCS 66.6 [95% CI 66.5–66.6], p = 0.002; PCS 66.3 [95% CI 66.2–66.4], p = 0.002; 39 studies, 24,600 participants; transplant: MCS 50.0 [95% CI 49.9–50.1], p = 0.002; PCS 48.0 [95% CI 47.9–48.1], p = 0.002; 39 studies, 9,664 participants). Limitations of the analysis are the relatively few studies contributing to symptom severity estimates and inconsistent use of PROMs (different measures and time points) across the included literature, which h
背景:在慢性肾脏疾病(CKD)人群中,患者报告的结果测量的重要性已经确立。然而,仍然缺乏综合全球ckd特定症状和健康相关生活质量(HRQOL)负担数据的研究,以最大限度地减少患者负担的方式,为最相关的患者重要信息的集中测量提供信息。本综述的目的是综合全球以下CKD临床组的症状患病率/严重程度和HRQOL数据:(1)1 - 5期未接受肾脏替代治疗(RRT),(2)接受透析治疗,或(3)接受肾移植。方法和研究结果检索MEDLINE、PsycINFO和CINAHL,检索2000年1月至2021年9月间发表的报告CKD患病率和/或症状严重程度和/或HRQOL的英文横断面/纵向研究,包括CKD成年患者,并使用患者报告的结果测量(PROM)测量症状患病率/严重程度和/或HRQOL。随机效应荟萃分析用于汇总数据,按CKD组分层:未接受RRT,接受透析或接受肾移植。纳入研究的方法学质量采用乔安娜布里格斯研究所报告患病率数据的研究关键评估清单进行评估,并对发表偏倚进行了探索。这项研究确定了1529项研究,其中449项,来自62个国家的199147名参与者,被纳入了分析。研究使用67种不同的症状和HRQOL结果测量,提供了68种报告症状的数据。随机效应荟萃分析强调了与CKD相关的相当大的症状和HRQOL负担,疲劳尤其普遍,无论是在未接受RRT的患者(14项研究,4139名参与者:70%,95% CI 60%-79%)还是接受透析的患者(21项研究,2943名参与者:70%,95% CI 64%-76%)。在移植后人群中,许多症状明显(经多次测试调整后p < 0.05)不那么普遍和/或不那么严重,这可能提示CKD的原因(疲劳、抑郁、瘙痒、活动能力差、睡眠差和口干)。透析患者的生活质量通常较低(36-Item Short - Form Health Survey [SF-36] Mental Component Summary [MCS] 45.7 [95% CI 45.5-45.8];SF-36物理部件概要[PCS] 35.5 [95% CI 35.3-35.6];91项研究,32,105名MCS和PCS患者)比其他CKD人群(未接受RRT的患者:SF-36 MCS 66.6 [95% CI 66.5-66.6], p = 0.002;PCS 66.3 [95% CI 66.2-66.4], p = 0.002;39项研究,24,600名参与者;移植:MCS 50.0 [95% CI 49.9-50.1], p = 0.002;PCS 48.0 [95% CI 47.9-48.1], p = 0.002;39项研究,9664名参与者)。分析的局限性是相对较少的研究有助于症状严重程度的估计,并且在所纳入的文献中使用的PROMs(不同的测量和时间点)不一致,这阻碍了解释。结论主要研究结果表明CKD患者有明显的症状和HRQOL负担。该综合报告提供了临床组间症状/HRQOL概况的详细概述,可以为医疗保健专业人员在讨论、测量和管理与CKD相关的潜在治疗负担时提供支持。协议注册PROSPERO CRD42020164737。
{"title":"Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis","authors":"B. Fletcher, Sarah Damery, O. Aiyegbusi, N. Anderson, M. Calvert, P. Cockwell, James Ferguson, M. Horton, Muirne C. S. Paap, C. Sidey-Gibbons, A. Slade, Neil Turner, D. Kyte","doi":"10.1371/journal.pmed.1003954","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003954","url":null,"abstract":"Background The importance of patient-reported outcome measurement in chronic kidney disease (CKD) populations has been established. However, there remains a lack of research that has synthesised data around CKD-specific symptom and health-related quality of life (HRQOL) burden globally, to inform focused measurement of the most relevant patient-important information in a way that minimises patient burden. The aim of this review was to synthesise symptom prevalence/severity and HRQOL data across the following CKD clinical groups globally: (1) stage 1–5 and not on renal replacement therapy (RRT), (2) receiving dialysis, or (3) in receipt of a kidney transplant. Methods and findings MEDLINE, PsycINFO, and CINAHL were searched for English-language cross-sectional/longitudinal studies reporting prevalence and/or severity of symptoms and/or HRQOL in CKD, published between January 2000 and September 2021, including adult patients with CKD, and measuring symptom prevalence/severity and/or HRQOL using a patient-reported outcome measure (PROM). Random effects meta-analyses were used to pool data, stratified by CKD group: not on RRT, receiving dialysis, or in receipt of a kidney transplant. Methodological quality of included studies was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data, and an exploration of publication bias performed. The search identified 1,529 studies, of which 449, with 199,147 participants from 62 countries, were included in the analysis. Studies used 67 different symptom and HRQOL outcome measures, which provided data on 68 reported symptoms. Random effects meta-analyses highlighted the considerable symptom and HRQOL burden associated with CKD, with fatigue particularly prevalent, both in patients not on RRT (14 studies, 4,139 participants: 70%, 95% CI 60%–79%) and those receiving dialysis (21 studies, 2,943 participants: 70%, 95% CI 64%–76%). A number of symptoms were significantly (p < 0.05 after adjustment for multiple testing) less prevalent and/or less severe within the post-transplantation population, which may suggest attribution to CKD (fatigue, depression, itching, poor mobility, poor sleep, and dry mouth). Quality of life was commonly lower in patients on dialysis (36-Item Short Form Health Survey [SF-36] Mental Component Summary [MCS] 45.7 [95% CI 45.5–45.8]; SF-36 Physical Component Summary [PCS] 35.5 [95% CI 35.3–35.6]; 91 studies, 32,105 participants for MCS and PCS) than in other CKD populations (patients not on RRT: SF-36 MCS 66.6 [95% CI 66.5–66.6], p = 0.002; PCS 66.3 [95% CI 66.2–66.4], p = 0.002; 39 studies, 24,600 participants; transplant: MCS 50.0 [95% CI 49.9–50.1], p = 0.002; PCS 48.0 [95% CI 47.9–48.1], p = 0.002; 39 studies, 9,664 participants). Limitations of the analysis are the relatively few studies contributing to symptom severity estimates and inconsistent use of PROMs (different measures and time points) across the included literature, which h","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41919368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 43
Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study 更正:英国大曼彻斯特地区COVID-19疫苗接种的种族不平等以及与季节性流感疫苗接种的比较:一项队列研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-04-01 DOI: 10.1371/journal.pmed.1003982
R. Watkinson, Richard Williams, Stephanie Gillibrand, Caroline Sanders, Matt Sutton
[This corrects the article DOI: 10.1371/journal.pmed.1003932.].
[更正文章DOI: 10.1371/journal.pmed.1003932.]。
{"title":"Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study","authors":"R. Watkinson, Richard Williams, Stephanie Gillibrand, Caroline Sanders, Matt Sutton","doi":"10.1371/journal.pmed.1003982","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003982","url":null,"abstract":"[This corrects the article DOI: 10.1371/journal.pmed.1003932.].","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48327650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Simplified hypertension screening methods across 60 countries: An observational study 60个国家简化高血压筛查方法:一项观察性研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-04-01 DOI: 10.1371/journal.pmed.1003975
R. Carrillo-Larco, W. C. Guzman-Vilca, D. Neupane
Background Simplified blood pressure (BP) screening approaches have been proposed. However, evidence is limited to a few countries and has not documented the cardiovascular risk amongst missed hypertension cases, limiting the uptake of these simplified approaches. We quantified the proportion of missed, over-diagnosed, and consistently identified hypertension cases and the 10-year cardiovascular risk in these groups. Methods and findings We used 60 WHO STEPS surveys (cross-sectional and nationally representative; n = 145,174) conducted in 60 countries in 6 world regions between 2004 and 2019. Nine simplified approaches were compared against the standard (average of the last 2 of 3 BP measurements). The 10-year cardiovascular risk was computed with the 2019 World Health Organization Cardiovascular Risk Charts. We used t tests to compare the cardiovascular risk between the missed and over-diagnosed cases and the consistent hypertension cases. We used Poisson multilevel regressions to identify risk factors for missed cases (adjusted for age, sex, body mass index, and 10-year cardiovascular risk). Across all countries, compared to the standard approach, the simplified approach that missed the fewest cases was using the second BP reading if the first BP reading was 130–145/80–95 mm Hg (5.62%); using only the second BP reading missed 5.82%. The simplified approach with the smallest over-diagnosis proportion was using the second BP reading if the first BP measurement was ≥140/90 mm Hg (3.03%). In many countries, cardiovascular risk was not significantly different between the missed and consistent hypertension groups, yet the mean was slightly lower amongst missed cases. Cardiovascular risk was positively associated with missed hypertension depending on the simplified approach. The main limitation of the work is the cross-sectional design. Conclusions Simplified BP screening approaches seem to have low misdiagnosis rates, and cardiovascular risk could be lower amongst missed cases than amongst consistent hypertension cases. Simplified BP screening approaches could be included in large screening programmes and busy clinics.
背景:简化的血压(BP)筛查方法已经被提出。然而,证据仅限于少数国家,并没有记录遗漏高血压病例中的心血管风险,限制了这些简化方法的采用。我们量化了这些组中漏诊、过度诊断和一致确定的高血压病例和10年心血管风险的比例。方法和发现我们使用了60项WHO STEPS调查(横断面和全国代表性;N = 145,174),于2004年至2019年在6个世界地区的60个国家进行。将9种简化方法与标准方法(3次BP测量的最后2次的平均值)进行比较。10年心血管风险是根据2019年世界卫生组织心血管风险图表计算的。我们使用t检验比较漏诊和过度诊断病例与一贯高血压病例的心血管风险。我们使用泊松多水平回归来确定漏诊病例的危险因素(调整年龄、性别、体重指数和10年心血管风险)。在所有国家,与标准方法相比,如果第一次血压读数为130-145/80-95 mm Hg,则使用第二次血压读数的简化方法漏报率最少(5.62%);仅使用第二次BP读数就错过了5.82%。如果第一次血压测量≥140/90 mm Hg,则使用第二次血压读数(3.03%)是过度诊断比例最小的简化方法。在许多国家,漏诊组和持续高血压组之间的心血管风险没有显著差异,但漏诊病例的平均值略低。根据简化方法,心血管风险与漏诊高血压呈正相关。该作品的主要限制是截面设计。结论简化血压筛查方法的误诊率较低,漏诊病例的心血管风险低于一致性高血压病例。简化的BP筛查方法可以纳入大型筛查计划和繁忙的诊所。
{"title":"Simplified hypertension screening methods across 60 countries: An observational study","authors":"R. Carrillo-Larco, W. C. Guzman-Vilca, D. Neupane","doi":"10.1371/journal.pmed.1003975","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003975","url":null,"abstract":"Background Simplified blood pressure (BP) screening approaches have been proposed. However, evidence is limited to a few countries and has not documented the cardiovascular risk amongst missed hypertension cases, limiting the uptake of these simplified approaches. We quantified the proportion of missed, over-diagnosed, and consistently identified hypertension cases and the 10-year cardiovascular risk in these groups. Methods and findings We used 60 WHO STEPS surveys (cross-sectional and nationally representative; n = 145,174) conducted in 60 countries in 6 world regions between 2004 and 2019. Nine simplified approaches were compared against the standard (average of the last 2 of 3 BP measurements). The 10-year cardiovascular risk was computed with the 2019 World Health Organization Cardiovascular Risk Charts. We used t tests to compare the cardiovascular risk between the missed and over-diagnosed cases and the consistent hypertension cases. We used Poisson multilevel regressions to identify risk factors for missed cases (adjusted for age, sex, body mass index, and 10-year cardiovascular risk). Across all countries, compared to the standard approach, the simplified approach that missed the fewest cases was using the second BP reading if the first BP reading was 130–145/80–95 mm Hg (5.62%); using only the second BP reading missed 5.82%. The simplified approach with the smallest over-diagnosis proportion was using the second BP reading if the first BP measurement was ≥140/90 mm Hg (3.03%). In many countries, cardiovascular risk was not significantly different between the missed and consistent hypertension groups, yet the mean was slightly lower amongst missed cases. Cardiovascular risk was positively associated with missed hypertension depending on the simplified approach. The main limitation of the work is the cross-sectional design. Conclusions Simplified BP screening approaches seem to have low misdiagnosis rates, and cardiovascular risk could be lower amongst missed cases than amongst consistent hypertension cases. Simplified BP screening approaches could be included in large screening programmes and busy clinics.","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44454997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Effectiveness of a brief group behavioral intervention for common mental disorders in Syrian refugees in Jordan: A randomized controlled trial. 约旦叙利亚难民常见精神障碍短期群体行为干预的有效性:一项随机对照试验
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-03-17 eCollection Date: 2022-03-01 DOI: 10.1371/journal.pmed.1003949
Richard A Bryant, Ahmad Bawaneh, Manar Awwad, Hadeel Al-Hayek, Luana Giardinelli, Claire Whitney, Mark J D Jordans, Pim Cuijpers, Marit Sijbrandij, Peter Ventevogel, Katie Dawson, Aemal Akhtar

Background: Common mental disorders are frequently experienced by refugees. This study evaluates the impact of a brief, lay provider delivered group-based psychological intervention [Group Problem Management Plus (gPM+)] on the mental health of refugees in a camp, as well as on parenting behavior and children's mental health.

Methods and findings: In this single-blind, parallel, randomized controlled trial, 410 adult Syrian refugees (300 females, 110 males) in Azraq Refugee Camp (Jordan) were identified through screening of psychological distress (≥16 on the Kessler Psychological Distress Scale) and impaired functioning (≥17 on the WHO Disability Assessment Schedule). Participants were randomly allocated to gPM+ or enhanced usual care (EUC) involving referral information for psychosocial services on a 1:1 ratio. Participants were aware of treatment allocation, but assessors were blinded to treatment condition. Primary outcomes were scores on the Hopkins Symptom Checklist-25 (HSCL; depression and anxiety scales) assessed at baseline, 6 weeks, and 3 months follow-up as the primary outcome time point. It was hypothesized that gPM+ would result in greater reductions of scores on the HSCL than EUC. Secondary outcomes were disability, posttraumatic stress, personally identified problems, prolonged grief, prodromal psychotic symptoms, parenting behavior, and children's mental health. Between October 15, 2019 and March 2, 2020, 624 refugees were screened for eligibility, 462 (74.0%) screened positive, of whom 204 were assigned to gPM+ and 206 to EUC. There were 168 (82.4%) participants in gPM+ and 189 (91.7%) in EUC assessed at follow-up. Intent-to-treat analyses indicated that at follow-up, participants in gPM+ showed greater reduction on HSCL depression scale than those receiving EUC (mean difference, 3.69 [95% CI 1.90 to 5.48], p = .001; effect size, 0.40). There was no difference between conditions in anxiety (mean difference -0.56, 95% CI -2.09 to 0.96; p = .47; effect size, -0.03). Relative to EUC, participants in gPM+ had greater reductions in severity of personally identified problems (mean difference 0.88, 95% CI 0.07 to 1.69; p = .03), and inconsistent disciplinary parenting (mean difference 1.54, 95% CI 1.03 to 2.05; p < .001). There were no significant differences between conditions for changes in PTSD, disability, grief, prodromal symptoms, or childhood mental health outcomes. Mediation analysis indicated the change in inconsistent disciplinary parenting was associated with reduced attentional (β = 0.11, SE .07; 95% CI .003 to .274) and internalizing (β = 0.08, SE .05; 95% CI .003 to 0.19) problems in children. No adverse events were attributable to the interventions or the trial. Major limitations included only one-quarter of participants being male, and measures of personally identified problems, grief, prodromal psychotic symptoms, inconsistent parenting behavior, and children's mental health hav

背景难民经常经历常见的精神障碍。本研究评估了由非专业人员提供的基于小组的简短心理干预[小组问题管理+(gPM+)]对难民营中难民心理健康的影响,以及对父母行为和儿童心理健康的影响力。方法和结果在这项单盲、平行、随机对照试验中,通过筛查心理困扰(Kessler心理困扰量表≥16)和功能障碍(世界卫生组织残疾评估表≥17),确定了约旦Azraq难民营的410名成年叙利亚难民(300名女性,110名男性)。参与者被随机分配到gPM+或强化常规护理(EUC),涉及心理社会服务的转诊信息,比例为1:1。参与者知道治疗分配,但评估人员对治疗情况一无所知。主要结果是在基线、6周和3个月随访时评估的霍普金斯症状检查表-25(HSCL;抑郁和焦虑量表)得分,作为主要结果时间点。假设gPM+将导致HSCL上的分数比EUC上的分数减少得更多。次要结果是残疾、创伤后压力、个人识别的问题、长期悲伤、前驱精神病症状、父母行为和儿童心理健康。在2019年10月15日至2020年3月2日期间,624名难民接受了资格筛查,462人(74.0%)筛查呈阳性,其中204人被分配到gPM+,206人被分配给EUC。随访时评估的gPM+参与者有168人(82.4%),EUC参与者有189人(91.7%)。意向治疗分析表明,在随访中,gPM+参与者在HSCL抑郁量表上的下降幅度大于接受EUC的参与者(平均差异3.69[95%CI 1.90至5.48],p=0.001;效应大小,0.40)。焦虑状况之间没有差异(平均差异-0.56,95%CI−2.09至0.96;p=.47;效应大小−0.03)。相对于EUC,gPM+的参与者在个人识别问题的严重程度(平均差异0.88,95%CI 0.07至1.69;p=0.03)和不一致的管教(平均差异1.54,95%CI 1.03至2.05;p<.001)方面有更大的降低。PTSD、残疾、悲伤、前驱症状或儿童心理健康结果的变化条件之间没有显著差异。中介分析表明,管教不一致的育儿方式的变化与儿童注意力(β=0.11,SE.07;95%CI.003-.274)和内化(β=0.08,SE.05;95%CI.003-0.19)问题的减少有关。没有不良事件可归因于干预或试验。主要局限性包括只有四分之一的参与者是男性,叙利亚人尚未对个人识别的问题、悲伤、前驱精神病症状、不一致的育儿行为和儿童心理健康进行验证。结论在难民营的叙利亚难民中,与常规护理相比,短暂的集体行为干预可以减少抑郁症状、个人发现的问题和纪律性育儿,这可能对难民的孩子有间接好处。减少创伤后应激障碍、残疾或儿童心理问题的干预能力有限,这表明需要为难民营环境中的难民开发更有效的治疗方法。试验注册在澳大利亚和新西兰临床试验注册处前瞻性注册:ACTRN12619001386123。
{"title":"Effectiveness of a brief group behavioral intervention for common mental disorders in Syrian refugees in Jordan: A randomized controlled trial.","authors":"Richard A Bryant,&nbsp;Ahmad Bawaneh,&nbsp;Manar Awwad,&nbsp;Hadeel Al-Hayek,&nbsp;Luana Giardinelli,&nbsp;Claire Whitney,&nbsp;Mark J D Jordans,&nbsp;Pim Cuijpers,&nbsp;Marit Sijbrandij,&nbsp;Peter Ventevogel,&nbsp;Katie Dawson,&nbsp;Aemal Akhtar","doi":"10.1371/journal.pmed.1003949","DOIUrl":"10.1371/journal.pmed.1003949","url":null,"abstract":"<p><strong>Background: </strong>Common mental disorders are frequently experienced by refugees. This study evaluates the impact of a brief, lay provider delivered group-based psychological intervention [Group Problem Management Plus (gPM+)] on the mental health of refugees in a camp, as well as on parenting behavior and children's mental health.</p><p><strong>Methods and findings: </strong>In this single-blind, parallel, randomized controlled trial, 410 adult Syrian refugees (300 females, 110 males) in Azraq Refugee Camp (Jordan) were identified through screening of psychological distress (≥16 on the Kessler Psychological Distress Scale) and impaired functioning (≥17 on the WHO Disability Assessment Schedule). Participants were randomly allocated to gPM+ or enhanced usual care (EUC) involving referral information for psychosocial services on a 1:1 ratio. Participants were aware of treatment allocation, but assessors were blinded to treatment condition. Primary outcomes were scores on the Hopkins Symptom Checklist-25 (HSCL; depression and anxiety scales) assessed at baseline, 6 weeks, and 3 months follow-up as the primary outcome time point. It was hypothesized that gPM+ would result in greater reductions of scores on the HSCL than EUC. Secondary outcomes were disability, posttraumatic stress, personally identified problems, prolonged grief, prodromal psychotic symptoms, parenting behavior, and children's mental health. Between October 15, 2019 and March 2, 2020, 624 refugees were screened for eligibility, 462 (74.0%) screened positive, of whom 204 were assigned to gPM+ and 206 to EUC. There were 168 (82.4%) participants in gPM+ and 189 (91.7%) in EUC assessed at follow-up. Intent-to-treat analyses indicated that at follow-up, participants in gPM+ showed greater reduction on HSCL depression scale than those receiving EUC (mean difference, 3.69 [95% CI 1.90 to 5.48], p = .001; effect size, 0.40). There was no difference between conditions in anxiety (mean difference -0.56, 95% CI -2.09 to 0.96; p = .47; effect size, -0.03). Relative to EUC, participants in gPM+ had greater reductions in severity of personally identified problems (mean difference 0.88, 95% CI 0.07 to 1.69; p = .03), and inconsistent disciplinary parenting (mean difference 1.54, 95% CI 1.03 to 2.05; p < .001). There were no significant differences between conditions for changes in PTSD, disability, grief, prodromal symptoms, or childhood mental health outcomes. Mediation analysis indicated the change in inconsistent disciplinary parenting was associated with reduced attentional (β = 0.11, SE .07; 95% CI .003 to .274) and internalizing (β = 0.08, SE .05; 95% CI .003 to 0.19) problems in children. No adverse events were attributable to the interventions or the trial. Major limitations included only one-quarter of participants being male, and measures of personally identified problems, grief, prodromal psychotic symptoms, inconsistent parenting behavior, and children's mental health hav","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47531043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
A comparison over 2 decades of disability-free life expectancy at age 65 years for those with long-term conditions in England: Analysis of the 2 longitudinal Cognitive Function and Ageing Studies. 比较英国65岁长期疾病患者20多年无残疾预期寿命:两项纵向认知功能和老龄化研究的分析
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-03-15 eCollection Date: 2022-03-01 DOI: 10.1371/journal.pmed.1003936
Holly Q Bennett, Andrew Kingston, Ilianna Lourida, Louise Robinson, Lynne Corner, Carol Brayne, Fiona E Matthews, Carol Jagger

Background: Previous research has examined the improvements in healthy years if different health conditions are eliminated, but often with cross-sectional data, or for a limited number of conditions. We used longitudinal data to estimate disability-free life expectancy (DFLE) trends for older people with a broad number of health conditions, identify the conditions that would result in the greatest improvement in DFLE, and describe the contribution of the underlying transitions.

Methods and findings: The Cognitive Function and Ageing Studies (CFAS I and II) are both large population-based studies of those aged 65 years or over in England with identical sampling strategies (CFAS I response 81.7%, N = 7,635; CFAS II response 54.7%, N = 7,762). CFAS I baseline interviews were conducted in 1991 to 1993 and CFAS II baseline interviews in 2008 to 2011, both with 2 years of follow-up. Disability was measured using the modified Townsend activities of daily living scale. Long-term conditions (LTCs-arthritis, cognitive impairment, coronary heart disease (CHD), diabetes, hearing difficulties, peripheral vascular disease (PVD), respiratory difficulties, stroke, and vision impairment) were self-reported. Multistate models estimated life expectancy (LE) and DFLE, stratified by sex and study and adjusted for age. DFLE was estimated from the transitions between disability-free and disability states at the baseline and 2-year follow-up interviews, and LE was estimated from mortality transitions up to 4.5 years after baseline. In CFAS I, 60.8% were women and average age was 75.6 years; in CFAS II, 56.1% were women and average age was 76.4 years. Cognitive impairment was the only LTC whose prevalence decreased over time (odds ratio: 0.6, 95% confidence interval (CI): 0.5 to 0.6, p < 0.001), and where the percentage of remaining years at age 65 years spent disability-free decreased for men (difference CFAS II-CFAS I: -3.6%, 95% CI: -8.2 to 1.0, p = 0.12) and women (difference CFAS II-CFAS I: -3.9%, 95% CI: -7.6 to 0.0, p = 0.04) with the LTC. For men and women with any other LTC, DFLE improved or remained similar. For women with CHD, years with disability decreased (-0.8 years, 95% CI: -3.1 to 1.6, p = 0.50) and DFLE increased (2.7 years, 95% CI: 0.7 to 4.7, p = 0.008), stemming from a reduction in the risk of incident disability (relative risk ratio: 0.6, 95% CI: 0.4 to 0.8, p = 0.004). The main limitations of the study were the self-report of health conditions and the response rate. However, inverse probability weights for baseline nonresponse and longitudinal attrition were used to ensure population representativeness.

Conclusions: In this study, we observed improvements to DFLE between 1991 and 2011 despite the presence of most health conditions we considered. Attention needs to be paid to support and care for people with cognitive impairment who had different outcomes to those with physical health

以前的研究已经检查了如果消除不同的健康状况,健康年的改善,但通常是横截面数据,或者是有限数量的状况。我们使用纵向数据来估计具有多种健康状况的老年人的无残疾预期寿命(DFLE)趋势,确定将导致DFLE最大改善的条件,并描述潜在转变的贡献。认知功能和衰老研究(CFAS I和II)都是基于英国65岁或以上人群的大型研究,采用相同的抽样策略(CFAS I应答81.7%,N = 7635;CFASⅱ应答54.7%,N = 7,762)。1991年至1993年进行了CFAS I基线访谈,2008年至2011年进行了CFAS II基线访谈,随访时间均为2年。使用改进的汤森日常生活活动量表来测量残疾。长期疾病(ltcs -关节炎、认知障碍、冠心病、糖尿病、听力困难、周围血管疾病、呼吸困难、中风和视力障碍)均为自我报告。多状态模型估计预期寿命(LE)和DFLE,按性别和研究分层,并根据年龄进行调整。从基线和2年随访访谈时无残疾状态和残疾状态之间的过渡估计DFLE,从基线后4.5年的死亡率过渡估计LE。第一组中女性占60.8%,平均年龄75.6岁;CFASⅱ中女性占56.1%,平均年龄76.4岁。认知障碍是唯一随时间下降的LTC(优势比:0.6,95%可信区间(CI): 0.5至0.6,p < 0.001),并且男性(CFAS II-CFAS I差异:- 3.6%,95% CI: - 8.2至1.0,p = 0.12)和女性(CFAS II-CFAS I差异:- 3.9%,95% CI: - 7.6至0.0,p = 0.04)在65岁时无残疾的剩余年数百分比随LTC下降。对于患有其他LTC的男性和女性,DFLE有所改善或保持相似。对于患有冠心病的女性,残疾的年数减少了(- 0.8年,95% CI: - 3.1至1.6,p = 0.50), DFLE增加了(2.7年,95% CI: 0.7至4.7,p = 0.008),这是由于发生残疾的风险降低(相对风险比:0.6,95% CI: 0.4至0.8,p = 0.004)。本研究的主要局限性在于健康状况的自我报告和应答率。然而,使用基线无反应和纵向磨损的逆概率权重来确保人口代表性。在这项研究中,尽管存在我们考虑的大多数健康状况,但我们观察到1991年至2011年间DFLE有所改善。需要注意支持和照顾认知障碍患者,他们的结局与身体健康状况不同。
{"title":"A comparison over 2 decades of disability-free life expectancy at age 65 years for those with long-term conditions in England: Analysis of the 2 longitudinal Cognitive Function and Ageing Studies.","authors":"Holly Q Bennett, Andrew Kingston, Ilianna Lourida, Louise Robinson, Lynne Corner, Carol Brayne, Fiona E Matthews, Carol Jagger","doi":"10.1371/journal.pmed.1003936","DOIUrl":"10.1371/journal.pmed.1003936","url":null,"abstract":"<p><strong>Background: </strong>Previous research has examined the improvements in healthy years if different health conditions are eliminated, but often with cross-sectional data, or for a limited number of conditions. We used longitudinal data to estimate disability-free life expectancy (DFLE) trends for older people with a broad number of health conditions, identify the conditions that would result in the greatest improvement in DFLE, and describe the contribution of the underlying transitions.</p><p><strong>Methods and findings: </strong>The Cognitive Function and Ageing Studies (CFAS I and II) are both large population-based studies of those aged 65 years or over in England with identical sampling strategies (CFAS I response 81.7%, N = 7,635; CFAS II response 54.7%, N = 7,762). CFAS I baseline interviews were conducted in 1991 to 1993 and CFAS II baseline interviews in 2008 to 2011, both with 2 years of follow-up. Disability was measured using the modified Townsend activities of daily living scale. Long-term conditions (LTCs-arthritis, cognitive impairment, coronary heart disease (CHD), diabetes, hearing difficulties, peripheral vascular disease (PVD), respiratory difficulties, stroke, and vision impairment) were self-reported. Multistate models estimated life expectancy (LE) and DFLE, stratified by sex and study and adjusted for age. DFLE was estimated from the transitions between disability-free and disability states at the baseline and 2-year follow-up interviews, and LE was estimated from mortality transitions up to 4.5 years after baseline. In CFAS I, 60.8% were women and average age was 75.6 years; in CFAS II, 56.1% were women and average age was 76.4 years. Cognitive impairment was the only LTC whose prevalence decreased over time (odds ratio: 0.6, 95% confidence interval (CI): 0.5 to 0.6, p < 0.001), and where the percentage of remaining years at age 65 years spent disability-free decreased for men (difference CFAS II-CFAS I: -3.6%, 95% CI: -8.2 to 1.0, p = 0.12) and women (difference CFAS II-CFAS I: -3.9%, 95% CI: -7.6 to 0.0, p = 0.04) with the LTC. For men and women with any other LTC, DFLE improved or remained similar. For women with CHD, years with disability decreased (-0.8 years, 95% CI: -3.1 to 1.6, p = 0.50) and DFLE increased (2.7 years, 95% CI: 0.7 to 4.7, p = 0.008), stemming from a reduction in the risk of incident disability (relative risk ratio: 0.6, 95% CI: 0.4 to 0.8, p = 0.004). The main limitations of the study were the self-report of health conditions and the response rate. However, inverse probability weights for baseline nonresponse and longitudinal attrition were used to ensure population representativeness.</p><p><strong>Conclusions: </strong>In this study, we observed improvements to DFLE between 1991 and 2011 despite the presence of most health conditions we considered. Attention needs to be paid to support and care for people with cognitive impairment who had different outcomes to those with physical health","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":10.5,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47865723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventions to reengage people living with HIV who are lost to follow-up from HIV treatment programs: A systematic review and meta-analysis. 对失去 HIV 治疗项目随访机会的 HIV 感染者采取干预措施:系统回顾与荟萃分析。
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-03-15 eCollection Date: 2022-03-01 DOI: 10.1371/journal.pmed.1003940
Ali Mirzazadeh, Ingrid Eshun-Wilson, Ryan R Thompson, Atousa Bonyani, James G Kahn, Stefan D Baral, Sheree Schwartz, George Rutherford, Elvin H Geng

Background: Optimizing services to facilitate engagement and retention in care of people living with HIV (PLWH) on antiretroviral therapies (ARTs) is critical to decrease HIV-related morbidity and mortality and HIV transmission. We systematically reviewed the literature for the effectiveness of implementation strategies to reestablish and subsequently retain clinical contact, improve viral load suppression, and reduce mortality among patients who had been lost to follow-up (LTFU) from HIV services.

Methods and findings: We searched 7 databases (PubMed, Cochrane, ERIC, PsycINFO, EMBASE, Web of Science, and the WHO regional databases) and 3 conference abstract archives (CROI, IAC, and IAS) to find randomized trials and observational studies published through 13 April 2020. Eligible studies included those involving children and adults who were diagnosed with HIV, had initiated ART, and were subsequently lost to care and that reported at least one review outcome (return to care, retention, viral suppression, or mortality). Data were extracted by 2 reviewers, with discrepancies resolved by a third. We characterized reengagement strategies according to how, where, and by whom tracing was conducted. We explored effects, first, among all categorized as LTFU from the HIV program (reengagement program effect) and second among those found to be alive and out of care (reengagement contact outcome). We used random-effect models for meta-analysis and conducted subgroup analyses to explore heterogeneity. Searches yielded 4,244 titles, resulting in 37 included studies (6 randomized trials and 31 observational studies). In low- and middle-income countries (LMICs) (N = 16), tracing most frequently involved identification of LTFU from the electronic medical record (EMR) and paper records followed by a combination of telephone calls and field tracing (including home visits), by a team of outreach workers within 3 months of becoming LTFU (N = 7), with few incorporating additional strategies to support reengagement beyond contact (N = 2). In high-income countries (HICs) (N = 21 studies), LTFU were similarly identified through EMR systems, at times matched with other public health records (N = 4), followed by telephone calls and letters sent by mail or email and conducted by outreach specialist teams. Home visits were less common (N = 7) than in LMICs, and additional reengagement support was similarly infrequent (N = 5). Overall, reengagement programs were able to return 39% (95% CI: 31% to 47%) of all patients who were characterized as LTFU (n = 29). Reengagement contact resulted in 58% (95% CI: 51% to 65%) return among those found to be alive and out of care (N = 17). In 9 studies that had a control condition, the return was higher among those in the reengagement intervention group than the standard of care group (RR: 1.20 (95% CI: 1.08 to 1.32, P < 0.001). There were insufficient data to generate pooled estimates of retenti

背景:优化服务以促进接受抗逆转录病毒疗法(ARTs)的艾滋病病毒感染者(PLWH)参与并继续接受治疗,对于降低艾滋病相关发病率和死亡率以及艾滋病病毒传播至关重要。我们系统地查阅了相关文献,以了解重新建立并随后保持临床联系、改善病毒载量抑制以及降低从艾滋病服务机构失去随访(LTFU)的患者死亡率的实施策略的有效性:我们检索了 7 个数据库(PubMed、Cochrane、ERIC、PsycINFO、EMBASE、Web of Science 和世界卫生组织地区数据库)和 3 个会议摘要档案库(CROI、IAC 和 IAS),以查找 2020 年 4 月 13 日之前发表的随机试验和观察性研究。符合条件的研究包括那些涉及儿童和成人的研究,这些儿童和成人被诊断出感染了艾滋病毒,开始接受抗逆转录病毒疗法,随后失去了治疗,并且至少报告了一项审查结果(重返治疗、保留治疗、病毒抑制或死亡率)。数据由两名审稿人提取,差异由第三名审稿人解决。我们根据追踪的方式、地点和追踪者来确定再参与策略的特点。我们首先探讨了所有被归类为从 HIV 项目中退出的患者的效果(再参与项目效果),其次探讨了被发现存活但未接受治疗的患者的效果(再参与接触结果)。我们使用随机效应模型进行了荟萃分析,并进行了亚组分析以探讨异质性。通过检索共获得 4,244 篇文章,最终纳入 37 项研究(6 项随机试验和 31 项观察性研究)。在中低收入国家(LMICs)(N = 16),追踪最常见的方式是从电子病历(EMR)和纸质病历中识别出失访患者,然后由外展工作者团队在失访患者失访 3 个月内结合电话和实地追踪(包括家访)(N = 7),很少有研究采用额外的策略来支持接触后的再参与(N = 2)。在高收入国家(HICs)(N = 21 项研究),LTFU 同样是通过 EMR 系统识别的,有时还与其他公共卫生记录相匹配(N = 4),然后由外联专家小组通过邮件或电子邮件拨打电话或发送信件。与低收入与中等收入国家相比,家访较少(7 次),额外的再参与支持也同样不多(5 次)。总体而言,在所有被定性为 "LTFU "的患者中,有 39% (95% CI:31% 至 47%)的患者能够重返再参与项目(N = 29)。重新参与接触项目使 58% (95% CI:51% 至 65%)被认定为仍在世但未接受治疗的患者重返医疗机构(N = 17)。在 9 项有对照条件的研究中,再参与干预组的重返率高于标准护理组(RR:1.20 (95% CI: 1.08 to 1.32, P < 0.001))。由于数据不足,无法对回归后的保留率、病毒抑制率或死亡率进行汇总估算:虽然干预措施的类型有明显的异质性,但再参与干预措施会增加重返护理的人数。艾滋病项目应考虑对系统进行投资,以更好地描述LTFU的特征,从而识别那些还活着但已脱离关怀的人,而进一步研究错过就诊后启动再参与工作的最佳时间,以及如何最好地支持持续的再参与,可以提高效率和效果。
{"title":"Interventions to reengage people living with HIV who are lost to follow-up from HIV treatment programs: A systematic review and meta-analysis.","authors":"Ali Mirzazadeh, Ingrid Eshun-Wilson, Ryan R Thompson, Atousa Bonyani, James G Kahn, Stefan D Baral, Sheree Schwartz, George Rutherford, Elvin H Geng","doi":"10.1371/journal.pmed.1003940","DOIUrl":"10.1371/journal.pmed.1003940","url":null,"abstract":"<p><strong>Background: </strong>Optimizing services to facilitate engagement and retention in care of people living with HIV (PLWH) on antiretroviral therapies (ARTs) is critical to decrease HIV-related morbidity and mortality and HIV transmission. We systematically reviewed the literature for the effectiveness of implementation strategies to reestablish and subsequently retain clinical contact, improve viral load suppression, and reduce mortality among patients who had been lost to follow-up (LTFU) from HIV services.</p><p><strong>Methods and findings: </strong>We searched 7 databases (PubMed, Cochrane, ERIC, PsycINFO, EMBASE, Web of Science, and the WHO regional databases) and 3 conference abstract archives (CROI, IAC, and IAS) to find randomized trials and observational studies published through 13 April 2020. Eligible studies included those involving children and adults who were diagnosed with HIV, had initiated ART, and were subsequently lost to care and that reported at least one review outcome (return to care, retention, viral suppression, or mortality). Data were extracted by 2 reviewers, with discrepancies resolved by a third. We characterized reengagement strategies according to how, where, and by whom tracing was conducted. We explored effects, first, among all categorized as LTFU from the HIV program (reengagement program effect) and second among those found to be alive and out of care (reengagement contact outcome). We used random-effect models for meta-analysis and conducted subgroup analyses to explore heterogeneity. Searches yielded 4,244 titles, resulting in 37 included studies (6 randomized trials and 31 observational studies). In low- and middle-income countries (LMICs) (N = 16), tracing most frequently involved identification of LTFU from the electronic medical record (EMR) and paper records followed by a combination of telephone calls and field tracing (including home visits), by a team of outreach workers within 3 months of becoming LTFU (N = 7), with few incorporating additional strategies to support reengagement beyond contact (N = 2). In high-income countries (HICs) (N = 21 studies), LTFU were similarly identified through EMR systems, at times matched with other public health records (N = 4), followed by telephone calls and letters sent by mail or email and conducted by outreach specialist teams. Home visits were less common (N = 7) than in LMICs, and additional reengagement support was similarly infrequent (N = 5). Overall, reengagement programs were able to return 39% (95% CI: 31% to 47%) of all patients who were characterized as LTFU (n = 29). Reengagement contact resulted in 58% (95% CI: 51% to 65%) return among those found to be alive and out of care (N = 17). In 9 studies that had a control condition, the return was higher among those in the reengagement intervention group than the standard of care group (RR: 1.20 (95% CI: 1.08 to 1.32, P < 0.001). There were insufficient data to generate pooled estimates of retenti","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":10.5,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66770058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis. 国家适应和实施世卫组织基本药物标准清单:定性证据综合
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-03-11 eCollection Date: 2022-03-01 DOI: 10.1371/journal.pmed.1003944
Elizabeth F Peacocke, Sonja L Myhre, Hakan Safaralilo Foss, Unni Gopinathan

Background: The World Health Organization Model List of Essential Medicines (WHO EML) has played a critical role in guiding the country-level selection and financing of medicines for more than 4 decades. It continues to be a relevant evidence-based policy that can support universal health coverage (UHC) and access to essential medicines. The objective of this review was to identify factors affecting adaptation and implementation of WHO EML at the national level.

Methods and findings: We conducted a qualitative evidence synthesis by searching 10 databases (including CINAHL, Embase, Ovid MEDLINE, Scopus, and Web of Science) through October 2021. Primary qualitative studies focused on country-level implementation of WHO EML were included. The qualitative findings were populated in the Supporting the Use of Research Evidence (SURE) framework, and key themes were identified through an iterative process. We appraised the papers using the Critical Appraisal Skills Programme (CASP) tool and assessed our confidence in the findings using the Grading of Recommendations Assessment, Development and Evaluation working group-Confidence in Evidence from Reviews of Qualitative research (GRADE-CERQual). We screened 1,567 unique citations, reviewed 183 full texts, and included 23 studies, from 30 settings. Non-English studies and experiences and perceptions of stakeholders published in gray literature were not collected. Our findings centered around 3 main ideas pertaining to national adaptation and implementation of WHO EML: (1) the importance of designing institutions, governance, and leadership for national medicines lists (NMLs), particularly the consideration of transparency, coordination capacity, legislative mechanisms, managing regional differences, and clinical guidance; (2) the capacity to manage evidence to inform NML updates, including processes for contextualizing global evidence, utilizing local data and expert knowledge, and assessing budget impact, to which locally relevant cost-effectiveness information plays an important role; and (3) the influence of NML on purchasing and prescribing by altering provider incentives, through linkages to systems for financing and procurement and donor influence.

Conclusions: This qualitative evidence synthesis underscores the complexity and interdependencies inherent to implementation of WHO EML. To maximize the value of NMLs, greater investments should be made in processes and institutions that are needed to support various stages of the implementation pathway from global norms to adjusting prescribed behavior. Moreover, further research on linkages between NMLs, procurement, and the availability of medicines will provide additional insight into optimal NML implementation.

Protocol registry: PROSPERO CRD42018104112.

背景40多年来,世界卫生组织基本药物示范清单(世界卫生组织EML)在指导国家一级药物选择和筹资方面发挥了重要作用。它仍然是一项相关的循证政策,可以支持全民健康覆盖和获得基本药物。本次审查的目的是确定影响世界卫生组织EML在国家一级的适应和实施的因素。方法和发现截至2021年10月,我们通过搜索10个数据库(包括CINAHL、Embase、Ovid MEDLINE、Scopus和Web of Science)进行了定性证据综合。主要的定性研究侧重于世界卫生组织EML在国家一级的实施。定性研究结果填充在支持使用研究证据(SURE)框架中,并通过迭代过程确定关键主题。我们使用批判性评估技能计划(CASP)工具对论文进行了评估,并使用建议分级评估、发展和评估工作组定性研究评审证据信心(GRADE CERQual)评估了我们对研究结果的信心。我们筛选了1567篇独特的引文,查阅了183篇全文,并纳入了来自30个环境的23项研究。未收集灰色文献中发表的非英语研究以及利益相关者的经验和看法。我们的研究结果集中在与世界卫生组织EML的国家适应和实施有关的3个主要想法上:(1)国家药品清单(NML)设计机构、治理和领导的重要性,特别是考虑透明度、协调能力、立法机制、管理区域差异和临床指导;(2) 管理证据以告知NML最新情况的能力,包括将全球证据纳入背景、利用当地数据和专家知识以及评估预算影响的过程,当地相关的成本效益信息在其中发挥着重要作用;以及(3)NML通过改变供应商激励措施,通过与融资和采购系统的联系以及捐助者的影响,对采购和处方产生的影响。结论这一定性证据综合突出了世界卫生组织EML实施的复杂性和相互依赖性。为了最大限度地提高NML的价值,应该对所需的流程和机构进行更多投资,以支持从全球规范到调整规定行为的实施路径的各个阶段。此外,对NML、采购和药品供应之间的联系进行进一步研究,将为NML的最佳实施提供更多见解。协议注册表PROSPERO CRD42018104112
{"title":"National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.","authors":"Elizabeth F Peacocke,&nbsp;Sonja L Myhre,&nbsp;Hakan Safaralilo Foss,&nbsp;Unni Gopinathan","doi":"10.1371/journal.pmed.1003944","DOIUrl":"10.1371/journal.pmed.1003944","url":null,"abstract":"<p><strong>Background: </strong>The World Health Organization Model List of Essential Medicines (WHO EML) has played a critical role in guiding the country-level selection and financing of medicines for more than 4 decades. It continues to be a relevant evidence-based policy that can support universal health coverage (UHC) and access to essential medicines. The objective of this review was to identify factors affecting adaptation and implementation of WHO EML at the national level.</p><p><strong>Methods and findings: </strong>We conducted a qualitative evidence synthesis by searching 10 databases (including CINAHL, Embase, Ovid MEDLINE, Scopus, and Web of Science) through October 2021. Primary qualitative studies focused on country-level implementation of WHO EML were included. The qualitative findings were populated in the Supporting the Use of Research Evidence (SURE) framework, and key themes were identified through an iterative process. We appraised the papers using the Critical Appraisal Skills Programme (CASP) tool and assessed our confidence in the findings using the Grading of Recommendations Assessment, Development and Evaluation working group-Confidence in Evidence from Reviews of Qualitative research (GRADE-CERQual). We screened 1,567 unique citations, reviewed 183 full texts, and included 23 studies, from 30 settings. Non-English studies and experiences and perceptions of stakeholders published in gray literature were not collected. Our findings centered around 3 main ideas pertaining to national adaptation and implementation of WHO EML: (1) the importance of designing institutions, governance, and leadership for national medicines lists (NMLs), particularly the consideration of transparency, coordination capacity, legislative mechanisms, managing regional differences, and clinical guidance; (2) the capacity to manage evidence to inform NML updates, including processes for contextualizing global evidence, utilizing local data and expert knowledge, and assessing budget impact, to which locally relevant cost-effectiveness information plays an important role; and (3) the influence of NML on purchasing and prescribing by altering provider incentives, through linkages to systems for financing and procurement and donor influence.</p><p><strong>Conclusions: </strong>This qualitative evidence synthesis underscores the complexity and interdependencies inherent to implementation of WHO EML. To maximize the value of NMLs, greater investments should be made in processes and institutions that are needed to support various stages of the implementation pathway from global norms to adjusting prescribed behavior. Moreover, further research on linkages between NMLs, procurement, and the availability of medicines will provide additional insight into optimal NML implementation.</p><p><strong>Protocol registry: </strong>PROSPERO CRD42018104112.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45463624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Reproductive health among married and unmarried mothers aged less than 18, 18-19, and 20-24 years in the United States, 2014-2019: A population-based cross-sectional study. 2014-2019年美国18岁、18 - 19岁和20-24岁以下已婚和未婚母亲的生殖健康:一项基于人群的横断面研究
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-03-10 eCollection Date: 2022-03-01 DOI: 10.1371/journal.pmed.1003929
Andrée-Anne Fafard St-Germain, Russell S Kirby, Marcelo L Urquia

Background: Studies in low- and middle-income regions suggest that child marriage (<18 years) is a risk factor for poor reproductive outcomes among women. However, in high-income-country contexts where childbearing before age 18 occurs predominantly outside marriage, it is unknown whether marriage is adversely associated with reproductive health among mothers below age 18. This study examined the joint associations of marriage and adolescent maternal age group (<18, 18-19, and 20-24 years) with reproductive, maternal, and infant health indicators in the United States.

Methods and findings: Birth registrations with US resident mothers aged ≤24 years with complete information on marital status were drawn from the 2014 to 2019 Natality Public Use Files (n = 5,669,824). Odds ratios for the interaction between marital status and maternal age group were estimated using multivariable logistic regression, adjusting for covariates such as maternal race/ethnicity and nativity status, federal program participation, and paternal age. Marriage prevalence was 3.6%, 13.2%, and 34.1% among births to mothers aged <18, 18-19, and 20-24 years, respectively. Age gradients in the adjusted odds ratios (AORs) were present for most indicators, and many gradients differed by marital status. Among births to mothers aged <18 years, marriage was associated with greater adjusted odds of prior pregnancy termination (AOR 1.64, 95% CI 1.52-1.77, p < 0.001), repeat birth (AOR 2.84, 95% CI 2.68-3.00, p < 0.001), maternal smoking (AOR 1.24, 95% CI 1.15-1.35, p < 0.001), and infant morbidity (AOR 1.07, 95% CI 1.01-1.14, p = 0.03), but weaker or reverse associations existed among births to older mothers. For all maternal age groups, marriage was associated with lower adjusted odds of late or no prenatal care initiation, sexually transmitted infection, and no breastfeeding at hospital discharge, but these beneficial associations were weaker among births to mothers aged <18 and 18-19 years. Limitations of the study include its cross-sectional nature and lack of information on marriage timing relative to prior pregnancy events.

Conclusions: Marriage among mothers below age 18 is associated with both adverse and favorable reproductive, maternal, and infant health indicators. Heterogeneity exists in the relationship between marriage and reproductive health across adolescent maternal age groups, suggesting girl child marriages must be examined separately from marriages at older ages.

背景低收入和中等收入地区的研究表明,童婚(<18岁)是妇女生殖结果不佳的一个风险因素。然而,在高收入国家,18岁之前的生育主要发生在婚外,尚不清楚18岁以下母亲的婚姻是否与生殖健康有不利关系。这项研究调查了美国婚姻和青少年产妇年龄组(<18、18-19和20-24岁)与生殖、孕产妇和婴儿健康指标的联合关系。方法和结果从2014年至2019年的出生公共使用档案(n=5669824)中提取了年龄≤24岁、婚姻状况信息完整的美国居民母亲的出生登记。使用多变量逻辑回归估计婚姻状况和母亲年龄组之间相互作用的比值比,并对协变量进行调整,如母亲种族/民族和出生状况、联邦项目参与度和父亲年龄。在18岁以下、18-19岁和20-24岁以下的母亲中,结婚率分别为3.6%、13.2%和34.1%。大多数指标都存在调整后比值比(AOR)中的年龄梯度,许多梯度因婚姻状况而异。在18岁以下母亲的分娩中,婚姻与更大的调整后终止妊娠几率(AOR 1.64,95%CI 1.52–1.77,p<0.001)、重复分娩几率(AOR2.84,95%CI2.68–3.00,p<001)、母亲吸烟几率(AOR1.24,95%CI 1.15–1.35,p>0.001)和婴儿发病率(AOR1.07,95%CI1.01–1.14,p=0.03)相关,但年龄较大的母亲所生的孩子之间存在较弱或相反的关联。对于所有产妇年龄组,结婚与延迟或没有开始产前护理、性传播感染和出院时没有母乳喂养的调整后几率较低有关,但在18岁和18-19岁以下的母亲中,这些有益的关联较弱。该研究的局限性包括其横断面性质以及缺乏与先前妊娠事件相关的结婚时间信息。结论18岁以下母亲结婚与不良和有利的生殖、孕产妇和婴儿健康指标有关。不同年龄段青少年的婚姻与生殖健康之间存在着异质性,这表明必须将女童婚姻与老年婚姻分开进行审查。
{"title":"Reproductive health among married and unmarried mothers aged less than 18, 18-19, and 20-24 years in the United States, 2014-2019: A population-based cross-sectional study.","authors":"Andrée-Anne Fafard St-Germain, Russell S Kirby, Marcelo L Urquia","doi":"10.1371/journal.pmed.1003929","DOIUrl":"10.1371/journal.pmed.1003929","url":null,"abstract":"<p><strong>Background: </strong>Studies in low- and middle-income regions suggest that child marriage (<18 years) is a risk factor for poor reproductive outcomes among women. However, in high-income-country contexts where childbearing before age 18 occurs predominantly outside marriage, it is unknown whether marriage is adversely associated with reproductive health among mothers below age 18. This study examined the joint associations of marriage and adolescent maternal age group (<18, 18-19, and 20-24 years) with reproductive, maternal, and infant health indicators in the United States.</p><p><strong>Methods and findings: </strong>Birth registrations with US resident mothers aged ≤24 years with complete information on marital status were drawn from the 2014 to 2019 Natality Public Use Files (n = 5,669,824). Odds ratios for the interaction between marital status and maternal age group were estimated using multivariable logistic regression, adjusting for covariates such as maternal race/ethnicity and nativity status, federal program participation, and paternal age. Marriage prevalence was 3.6%, 13.2%, and 34.1% among births to mothers aged <18, 18-19, and 20-24 years, respectively. Age gradients in the adjusted odds ratios (AORs) were present for most indicators, and many gradients differed by marital status. Among births to mothers aged <18 years, marriage was associated with greater adjusted odds of prior pregnancy termination (AOR 1.64, 95% CI 1.52-1.77, p < 0.001), repeat birth (AOR 2.84, 95% CI 2.68-3.00, p < 0.001), maternal smoking (AOR 1.24, 95% CI 1.15-1.35, p < 0.001), and infant morbidity (AOR 1.07, 95% CI 1.01-1.14, p = 0.03), but weaker or reverse associations existed among births to older mothers. For all maternal age groups, marriage was associated with lower adjusted odds of late or no prenatal care initiation, sexually transmitted infection, and no breastfeeding at hospital discharge, but these beneficial associations were weaker among births to mothers aged <18 and 18-19 years. Limitations of the study include its cross-sectional nature and lack of information on marriage timing relative to prior pregnancy events.</p><p><strong>Conclusions: </strong>Marriage among mothers below age 18 is associated with both adverse and favorable reproductive, maternal, and infant health indicators. Heterogeneity exists in the relationship between marriage and reproductive health across adolescent maternal age groups, suggesting girl child marriages must be examined separately from marriages at older ages.</p>","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":10.5,"publicationDate":"2022-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48109650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case–control study 美国老年医疗保险受益人处方阿片类药物剂量轨迹和阿片类药相关不良事件风险:一项嵌套病例对照研究
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2022-03-01 DOI: 10.1371/journal.pmed.1003947
Y. Wei, Cheng Chen, Motomori O Lewis, S. Schmidt, A. Winterstein
Background Despite the rising number of older adults with medical encounters for opioid misuse, dependence, and poisoning, little is known about patterns of prescription opioid dose and their association with risk for opioid-related adverse events (ORAEs) in older patients. The study aims to compare trajectories of prescribed opioid doses in 6 months preceding an incident ORAE for cases and a matched control group of older patients with chronic noncancer pain (CNCP). Methods and findings We conducted a nested case–control study within a cohort of older (≥65 years) patients diagnosed with CNCP who were new users of prescription opioids, assembled using a 5% national random sample of Medicare beneficiaries from 2011 to 2018. From the cohort with a mean follow-up of 2.3 years, we identified 3,103 incident ORAE cases with ≥1 opioid prescription in 6 months preceding the event, and 3,103 controls matched on sex, age, and time since opioid initiation. Key exposure was trajectories of prescribed opioid morphine milligram equivalent (MME) daily dosage over 6 months before the incident ORAE or matched controls. Among the cases and controls, 2,192 (70.6%) were women, and the mean (SD) age was 77.1 (7.1) years. Four prescribed opioid trajectories before the incident ORAE diagnosis or matched date emerged: gradual dose discontinuation (from ≤3 to 0 daily MME, 1,456 [23.5%]), gradual dose increase (from 0 to >3 daily MME, 1,878 [30.3%]), consistent low dose (between 3 and 5 daily MME, 1,510 [24.3%]), and consistent moderate dose (>20 daily MME, 1,362 [22.0%]). Few older patients (<5%) were prescribed a mean daily dose of ≥90 daily MME during 6 months before diagnosis or matched date. Patients with gradual dose discontinuation versus those with a consistent low dose, moderate dose, and increase dose were more likely to be younger (65 to 74 years), Midwest US residents, and receiving no low-income subsidy. Compared to patients with gradual dose discontinuation, those with gradual dose increase (adjusted odds ratio [aOR] = 3.4; 95% confidence interval (CI) 2.8 to 4.0; P < 0.001), consistent low dose (aOR = 3.8; 95% CI 3.2 to 4.6; P < 0.001), and consistent moderate dose (aOR = 8.5; 95% CI 6.8 to 10.7; P < 0.001) had a higher risk of ORAE, after adjustment for covariates. Our main findings remained robust in the sensitivity analysis using a cohort study with inverse probability of treatment weighting analyses. Major limitations include the limited generalizability of the study findings and lack of information on illicit opioid use, which prevents understanding the clinical dose threshold level that increases the risk of ORAE in older adults. Conclusions In this sample of older patients who are Medicare beneficiaries, 4 prescription opioid dose trajectories were identified, with most prescribed doses below 90 daily MME within 6 months before ORAE or matched date. An increased risk for ORAE was observed among older patients with a gradual increase in dose or among
背景尽管越来越多的老年人因阿片类药物滥用、依赖和中毒而就医,但对处方阿片类药物剂量模式及其与老年患者阿片类药物相关不良事件(orae)风险的关系知之甚少。该研究旨在比较老年慢性非癌性疼痛(CNCP)患者在发生ORAE前6个月处方阿片类药物剂量的轨迹。方法和研究结果我们在2011年至2018年5%的全国随机医疗保险受益人中,对诊断为CNCP的老年(≥65岁)患者进行了巢式病例对照研究,这些患者是处方阿片类药物的新使用者。从平均随访2.3年的队列中,我们确定了3103例在事件发生前6个月内处方≥1种阿片类药物的ORAE病例,以及3103例性别、年龄和开始服用阿片类药物时间相匹配的对照组。关键暴露是处方阿片类吗啡毫克当量(MME)每日剂量在ORAE事件或匹配对照发生前6个月的轨迹。在病例和对照组中,女性2192例(70.6%),平均(SD)年龄为77.1岁。在ORAE事件诊断或匹配日期之前,出现了四种处方阿片类药物轨迹:逐渐停药(每日MME≤3至0,1,456例[23.5%]),逐渐增加剂量(每日MME从0至bb0.3, 1,878例[30.3%]),持续低剂量(每日MME 3至5例,1,510例[24.3%]),以及持续中等剂量(每日MME 3至20例,1,362例[22.0%])。少数老年患者(<5%)在诊断前6个月或匹配日期的平均日剂量≥90每日MME。逐渐停药的患者与持续低剂量、中剂量和增加剂量的患者相比,更可能是年龄较小(65至74岁)的美国中西部居民,并且没有接受低收入补贴。与逐渐停药的患者相比,逐渐增加剂量的患者(校正优势比[aOR] = 3.4;95%置信区间(CI) 2.8 ~ 4.0;P < 0.001),一致的低剂量(aOR = 3.8;95% CI 3.2 ~ 4.6;P < 0.001),一致的中等剂量(aOR = 8.5;95% CI 6.8 ~ 10.7;校正协变量后,P < 0.001)发生ORAE的风险较高。我们的主要发现在使用治疗加权逆概率分析的队列研究的敏感性分析中仍然稳健。主要限制包括研究结果的有限普遍性和缺乏关于非法阿片类药物使用的信息,这阻碍了对增加老年人ORAE风险的临床剂量阈值水平的了解。结论:在老年医保受益人样本中,确定了4种处方阿片类药物剂量轨迹,大多数处方剂量在ORAE或匹配日期前6个月内低于90每日MME。与停用阿片类药物的患者相比,逐渐增加阿片类药物剂量的老年患者或持续使用低至中等剂量阿片类药物的患者发生ORAE的风险增加。老年患者是否易受低剂量阿片类药物影响还有待进一步调查。
{"title":"Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case–control study","authors":"Y. Wei, Cheng Chen, Motomori O Lewis, S. Schmidt, A. Winterstein","doi":"10.1371/journal.pmed.1003947","DOIUrl":"https://doi.org/10.1371/journal.pmed.1003947","url":null,"abstract":"Background Despite the rising number of older adults with medical encounters for opioid misuse, dependence, and poisoning, little is known about patterns of prescription opioid dose and their association with risk for opioid-related adverse events (ORAEs) in older patients. The study aims to compare trajectories of prescribed opioid doses in 6 months preceding an incident ORAE for cases and a matched control group of older patients with chronic noncancer pain (CNCP). Methods and findings We conducted a nested case–control study within a cohort of older (≥65 years) patients diagnosed with CNCP who were new users of prescription opioids, assembled using a 5% national random sample of Medicare beneficiaries from 2011 to 2018. From the cohort with a mean follow-up of 2.3 years, we identified 3,103 incident ORAE cases with ≥1 opioid prescription in 6 months preceding the event, and 3,103 controls matched on sex, age, and time since opioid initiation. Key exposure was trajectories of prescribed opioid morphine milligram equivalent (MME) daily dosage over 6 months before the incident ORAE or matched controls. Among the cases and controls, 2,192 (70.6%) were women, and the mean (SD) age was 77.1 (7.1) years. Four prescribed opioid trajectories before the incident ORAE diagnosis or matched date emerged: gradual dose discontinuation (from ≤3 to 0 daily MME, 1,456 [23.5%]), gradual dose increase (from 0 to >3 daily MME, 1,878 [30.3%]), consistent low dose (between 3 and 5 daily MME, 1,510 [24.3%]), and consistent moderate dose (>20 daily MME, 1,362 [22.0%]). Few older patients (<5%) were prescribed a mean daily dose of ≥90 daily MME during 6 months before diagnosis or matched date. Patients with gradual dose discontinuation versus those with a consistent low dose, moderate dose, and increase dose were more likely to be younger (65 to 74 years), Midwest US residents, and receiving no low-income subsidy. Compared to patients with gradual dose discontinuation, those with gradual dose increase (adjusted odds ratio [aOR] = 3.4; 95% confidence interval (CI) 2.8 to 4.0; P < 0.001), consistent low dose (aOR = 3.8; 95% CI 3.2 to 4.6; P < 0.001), and consistent moderate dose (aOR = 8.5; 95% CI 6.8 to 10.7; P < 0.001) had a higher risk of ORAE, after adjustment for covariates. Our main findings remained robust in the sensitivity analysis using a cohort study with inverse probability of treatment weighting analyses. Major limitations include the limited generalizability of the study findings and lack of information on illicit opioid use, which prevents understanding the clinical dose threshold level that increases the risk of ORAE in older adults. Conclusions In this sample of older patients who are Medicare beneficiaries, 4 prescription opioid dose trajectories were identified, with most prescribed doses below 90 daily MME within 6 months before ORAE or matched date. An increased risk for ORAE was observed among older patients with a gradual increase in dose or among ","PeriodicalId":20368,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45834993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
PLoS Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1